Biogen Amevive Marketing Focus Will Be Duration Of Antipsoriatic Response
Executive Summary
Biogen will distinguish Amevive in the psoriasis market by emphasizing the biologic's duration of response following FDA approval Jan. 30
You may also be interested in...
Biogen Wants To Reduce Amevive Copay, Adds Pharmacy Distribution
Biogen is pursuing initiatives to reduce the copay burden for patients taking the psoriasis agent Amevive
Biogen Wants To Reduce Amevive Copay, Adds Pharmacy Distribution
Biogen is pursuing initiatives to reduce the copay burden for patients taking the psoriasis agent Amevive
Raptiva Manufacturing Issues Will Not Delay Approval, Launch – Genentech
Genentech expects the Raptiva manufacturing process to be ready in time for the biologic's late October user fee date, the company told investors Sept. 9